647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

Autor:	Cindy L. O'Bryant, F. Fox, E. Temmer, S. G. Eckhardt, L.Q. Chow, Lia Gore, H. Youssoufian, D.R. Camidge, Sami Diab, R.B. Cohen
Rok vydání:	2006
Předmět:	Anti vegf Cancer Research biology medicine.drug_class business.industry VEGF receptors Monoclonal antibody Advanced cancer Oncology Immunology medicine Cancer research Dose escalation biology.protein In patient Receptor business
Zdroj:	European Journal of Cancer Supplements. 4:195
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(06)70652-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e92fae7471eb92dce162d9583abca904 https://doi.org/10.1016/s1359-6349(06)70652-8 Zobrazit plný text záznamu Full Text from ScienceDirect